Asieris Pharmaceuticals
Asieris Pharmaceuticals has 1 licensing announcement in this dataset, dated 2026-10-07.
- Country / operating region
- China
- Ticker
- 688176.SH
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- asieris.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| APL-1702 (CEVIRA) | 查無 | 查無 | 查無 | 2026-10-07 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| APL-1702 (CEVIRA) | 查無 | — | 查無 | 查無 | 2026-10-07 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Theramex | APL-1702 (CEVIRA) | USD 15m | USD 11m | 查無 | 查無 | Potential total > USD 250m Conditional upfront: supply agreement, manufacturing audits, alignment with upstream agreement and European Commission clarification. |
| Counterparty | Territory | Royalties |
|---|---|---|
| Theramex | Europe, Australia, New Zealand and Turkey | Tiered royalties; rate not disclosed. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無